A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
Advanced Malignancies That Harbor IDHR132 Mutations
DRUG: IDH305
Incident rate of dose limiting toxicities (DLTs), To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE), 21 days
Incidence of adverse events (AEs), To characterize the safety and tolerability of IDH305, 30 months|Plasma PK parameters (AUC, Cmax, Tmax), To characterize the PK profile of IDH305, 30 months|Changes of 2-hydroxyglutarate concentration in patient specimens, To characterize the PD profile of IDH305, 30 months|Overall response rate (ORR), To assess any preliminary anti-tumor activity of IDH305, 30 months|Incidence of serious adverse events (SAE), To characterize the safety and tolerability of IDH305, 30 months
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.